IBJNews

Eli Lilly's profit shoots up despite lackluster sales

Back to TopCommentsE-mailPrintBookmark and Share

Shares of Eli Lilly and Co. fell about 3 percent in morning trading Wednesday after the drugmaker reported better-than-expected earnings, but flat revenue, for the first quarter.

Lilly also said regulators had agreed to a priority review of the company's potential stomach cancer treatment.

The Indianapolis-based company said the Food and Drug Administration will evaluate ramucirumab under a program designed for drugs that treat serious or life-threatening diseases for which there are few other therapies. Fast-track, or priority, status gives companies extra meetings and correspondence with regulators throughout the review process, and it allows the drugmaker to submit data as it compiles it.

Lilly is seeking approval for ramucirumab as a second treatment in patients with gastric and gastroesophageal junction cancers that have spread. Gastric cancer affects the stomach lining and often goes undetected while developing slowly. Gastroesophageal junction cancer forms where the esophagus connects to the stomach.

The company said last year that the experimental drug met goals for improved patient survival in late-stage clinical research.

Lilly also recently submitted a new type 2 diabetes treatment it developed with German drugmaker Boehringer Ingelheim to the FDA. The company said Wednesday that treatment and ramucirumab are the first two of what could be five drugs submitted to U.S. regulators this year.

Investors are watching Lilly's pipeline of developing drugs closely because the company is losing U.S. patent protection for some key products, and it needs to replace that revenue. Lilly lost patent protection for its all-time best selling drug, the antipsychotic Zyprexa, in late 2011, and its sales have plunged since being exposed to cheaper generic competition. The company also loses protection at the end of this year for current top-seller, the antidepressant Cymbalta.

In the first quarter, Lilly's earnings jumped 53 percent largely due to a $495 million payment for the transfer to former drug development partner Amylin Pharmaceuticals of commercial rights outside the United States for the diabetes treatment exenatide.

Lilly earned $1.55 billion, or $1.42 per share, in the three months that ended March 31. That compares to $1.01 billion, or 91 cents per share, in last year's quarter.

Not counting the exenatide payment, Lilly reported adjusted earnings of $1.14 per share. Analysts expected, on average, earnings of $1.05 per share, according to FactSet.

The drugmaker said its revenue stayed flat at $5.6 billion, as lower sales volume and unfavorable foreign exchange rates countered gains from higher prices. Analysts expected $5.67 billion in revenue.

Revenue from Cymbalta rose 19 percent, to $1.33 billion, and sales of the erectile dysfunction drug Cialis climbed 11 percent, to $515 million. But revenue from Zyprexa tumbled 49 percent, to $284.8 million.

The drugmaker also reaffirmed its forecast for 2013 earnings to range between $3.82 and $3.97 per share on $22.6 billion to $23.4 billion in revenue.

Analysts expect, on average, earnings of $3.90 per share on $23 billion in revenue.

Lilly shares were down 2.8 percent near midday, to $56.75 each. The company's stock price had risen 18.3 percent this yea after closing Tuesday at $58.33. It has been lifted by the broader markets and by investors’ rising hopes in the pipeline potential of all pharmaceutical companies.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. A Tilted Kilt at a water park themed hotel? Who planned that one? I guess the Dad's need something to do while the kids are on the water slides.

  2. Don't come down on the fair for offering drinks. This is a craft and certainly one that belongs in agriculture due to ingredients. And for those worrying about how much you can drink. I'm sure it's more to do with liability than anything else. They don't want people suing for being over served. If you want a buzz, do a little pre-drinking before you go.

  3. I don't drink but go into this "controlled area" so my friend can drink. They have their 3 drink limit and then I give my friend my 3 drink limit. How is the fair going to control this very likely situation????

  4. I feel the conditions of the alcohol sales are a bit heavy handed, but you need to realize this is the first year in quite some time that beer & wine will be sold at the fair. They're starting off slowly to get a gauge on how it will perform this year - I would assume if everything goes fine that they relax some of the limits in the next year or couple of years. That said, I think requiring the consumption of alcohol to only occur in the beer tent is a bit much. That is going to be an awkward situation for those with minors - "Honey, I'm getting a beer... Ok, sure go ahead... Alright see you in just a min- half an hour."

  5. This might be an effort on the part of the State Fair Board to manage the risk until they get a better feel for it. However, the blanket notion that alcohol should not be served at "family oriented" events is perhaps an oversimplification. and not too realistic. For 15 years, I was a volunteer at the Indianapolis Air Show, which was as family oriented an event as it gets. We sold beer donated by Monarch Beverage Company and served by licensed and trained employees of United Package Liquors who were unpaid volunteers. And where did that money go? To central Indiana children's charities, including Riley Hospital for Children! It's all about managing the risk.

ADVERTISEMENT